Coca-Cola Icecek (CCI) has returned to profits in the first quarter of the year, boosted by carbonated drinks.

For the three months to the end of March, CCI recorded net profits of TRY8.8m (US$5.7m) compared to losses of TRY58.8m in the prior year.

Profits were boosted by greater operating efficiency and lower non-cash foreign exchange losses from foreign currency denominated financial loans, the firm said today (11 May).

Group net sales for the quarter amounted to TRY445m, up by 1.3% on the prior year. International operations accounted for 20% of the total net sales in the first quarter.

Group sales volume increased by 8.6% for the period to reach 113m unit cases. Net sales per unit case however, declined by 6.7% to TRY3.95.

“I am very pleased to announce that CCI had a good start to the year,” said CEO Michael O’Neill. “Colder weather and the economic environment in the regions where we operate continue to present challenges. Even though the first quarter is our smallest reporting period, a good start to the year boosts our confidence and encourages optimism for the rest of the year.”

O’Neill said the firm is “confident and determined” that CCI is positioned to take advantage of emerging economic recovery.

Stay informed for just £1! *

Subscribe to Just Drinks for unbiased coverage of the global drinks industry, offering insights into the corporate strategies of beverage manufacturers and brands worldwide.


What’s included in your subscription:
  • Unlimited access to Just Drinks content including daily global news, in-depth analysis, and interviews with C-suite executives
  • Unbeatable coverage of categories from beer, wine and spirits to soft drinks and hot beverages
  • Unrivalled drinks industry comment from leading sector specialists

Ready to stay informed? Subscribe now and gain access to exclusive content.

Subscribe

Have a subscription? Sign in

For further details on subscribing, click here. Need multi-user access? Explore our corporate subscriptions now.

*After your 1-month trial, your subscription will continue at £315 per year.